Developer docs
API playgroundTry for free, no card

Search company profiles

Key2Brain

Full company profile

uuid000kp3l

Namestring
Key2Brain
Legal namestring
key2brain AB
Websiteurl
key2brain.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Key2Brain AB is a Swedish privately held biotechnology company founded in 2020 and headquartered at the Karolinska Institute Campus (Innomedicum, A Working Lab) in Solna, Stockholm. The company has developed a proprietary blood-brain barrier (BBB)-crossing platform technology based on small (<15 kDa) engineered single-domain VHH antibodies with monovalent specificity for the Transferrin Receptor (TfR). This modular platform is designed to be integrated with diverse therapeutic modalities — peptides, proteins, enzymes, monoclonal antibodies, and oligonucleotides — to enable efficient brain uptake and broad CNS distribution without disrupting disease target specificity.

Key2Brain operates a pure B2B licensing and collaboration business model. The company does not develop or commercialize its own therapeutic products; instead, it provides partners with worldwide, royalty-bearing licenses to combine its BBB shuttle technology with partner therapeutic candidates, while partners fund all research, development, and commercialization. Revenue streams take the form of upfront payments, development and sales-based milestones, and tiered royalties on potential sales, supplemented by collaborative research and option agreements. The customer base is concentrated among large pharmaceutical and specialty biotechnology companies — most notably Chiesi Group (Chiesi Global Rare Diseases) under a worldwide license for BBB-crossing enzyme replacement therapies in alpha-mannosidosis and Krabbe disease (June 2025), and OliX Pharmaceuticals under an evaluation and option agreement for CNS-targeted siRNA delivery (February 2026).

The company employs 1-10 staff, has received non-dilutive grant funding of up to SEK 4 million from VINNOVA (Sweden's Innovation Agency) under its Innovative Start-ups and Deeptech Acceleration programs, and reports no publicly disclosed equity financing. Its internal pipeline and partnered programs remain at the preclinical to early research stage.

Short descriptiontext

Key2Brain AB is a Swedish preclinical biotech developing a proprietary blood-brain barrier-crossing VHH antibody platform that delivers CNS therapeutics to pharmaceutical partners via worldwide licensing and collaboration agreements.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersStockholm, Sweden
HQ citystring
Stockholm
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
blood-brain barrier delivery, CNS drug delivery, VHH antibody platform, brain targeting therapeutics, enzyme replacement therapy
Industry1 code
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
CNS Drug Delivery Technology
Social media profiles1 record
Revenue model2 records
1Licensing Revenue
TypeLicensing Royalties
Description

Worldwide, royalty-bearing license agreements where Key2Brain provides technology access and receives upfront payments, development and sales-based milestone payments, and tiered royalties on potential sales. Partner funds all research, development, and subsequent commercialization worldwide.

key2brain.com
2Collaborative Research Payments
TypeLicensing Royalties
Description

Joint research agreements with option structures where Key2Brain conducts evaluation-based research alongside partners, with potential for future exclusive licensing rights upon successful technical validation.

key2brain.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Key2Brain develops and licenses a proprietary blood-brain barrier-crossing (BBB-crossing) platform technology based on small (<15 kDa) engineered single domain VHH antibodies that bind the Transferrin Receptor (TfR). The platform is modularly applied across peptides, proteins, enzymes, monoclonal antibodies, and oligonucleotides to enable efficient brain uptake and broad distribution of CNS therapeutics, and is commercialized through worldwide, royalty-bearing license agreements and collaborative research partnerships with pharmaceutical and biotechnology companies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Demonstrated efficient brain uptake and target engagement in preclinical models
Product overview1 text field

Key2Brain is a Swedish biotechnology company developing next-generation brain targeting therapeutics using its proprietary blood-brain barrier-crossing (BBB-crossing) platform technology. The platform consists of small (<15 kDa) engineered single domain VHH antibodies targeting the Transferrin Receptor (TfR), which can be integrated with various therapeutic modalities including peptides, proteins, enzymes, mAbs, and oligonucleotides. The company's pipeline programs include the aMann-K2B program for alpha-mannosidosis and BBB-crossing ERT programs for Krabbe disease, developed both internally and through partnerships with Chiesi Group and OliX Pharmaceuticals.

Product and service3 records
1BBB-Crossing Platform Technology
CategoryCNS drug delivery platform
Description

Proprietary blood-brain barrier-crossing technology based on small (<15 kDa) engineered single domain VHH antibodies with monovalent specificity for the Transferrin Receptor (TfR), enabling efficient brain uptake and broad distribution of CNS therapeutics across peptides, proteins, enzymes, mAbs, and oligonucleotides. Licensed to pharmaceutical and biotechnology partners for use in their therapeutic candidates.

2aMann-K2B Program
CategoryEnzyme replacement therapy pipeline program
Description

Blood-brain barrier-crossing recombinant enzyme replacement therapy program for alpha-mannosidosis, developed in collaboration with Chiesi Global Rare Diseases under a worldwide licensing agreement.

3Krabbe Disease BBB-Crossing ERT
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-10
Description

Strategic evaluation and option agreement to develop CNS-targeted siRNA therapeutics using Key2Brain's TfR-targeted BBB shuttle technology. Joint research to assess CNS delivery efficiency and technical suitability. OliX may exercise option for worldwide exclusive license for conjugates incorporating OliX siRNA candidate with Key2Brain's TfR-targeting platform for undisclosed CNS target. Marks Key2Brain's first siRNA collaboration, highlighting platform versatility.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-11
Description

Worldwide licensing agreement to advance two blood-brain barrier (BBB)-crossing recombinant enzyme replacement therapies (ERT) for lysosomal storage disorders including alpha-mannosidosis (aMann) and Krabbe disease (KD). Built on partnership initiated in 2022. Key2Brain receives upfront payment, development and sales-based milestone payments, and tiered royalties. Chiesi funds all research, development, and commercialization worldwide. Agreement includes framework to add additional enzymes to collaboration.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Arma Biosciences
TypeEmerging player
Description

Early-stage biotech developing TfR-based BBB shuttle technology for CNS drug delivery; an emerging player pursuing the same receptor-mediated delivery strategy as Key2Brain.

TypeDirect peer
Description

Clinical-stage US biotech developing engineered protein transport vehicles (TVs) targeting TfR1 to deliver therapeutics across the BBB - the most direct competitor to Key2Brain's VHH/TfR shuttle approach. Both companies pursue partner-funded CNS delivery platforms.

TypeDirect peer
Description

Japanese biopharma with its J-Brain Cargo BBB-penetrating antibody platform used to deliver enzyme replacement therapies across the BBB, including for lysosomal storage disorders - directly comparable to Key2Brain's Chiesi-partnered ERT programs.

TypeDirect peer
Description

French biotech whose BBB-shuttle vector platform delivers small molecules, peptides, proteins, and nucleic acids across the BBB via receptor-mediated transport - directly comparable modular shuttle technology to Key2Brain's VHH/TfR platform.

TypeDirect peer
Description

Swedish biotech developing CNS-targeted biologics (including brain-transport technologies for antibody delivery) with strong ties to the Karolinska ecosystem; a regional Swedish peer with overlapping BBB delivery and CNS focus.

TypeBroad incumbent
Description

Large incumbent running the Brainshuttle (TfR-based) program with various partners, including in CNS; broader portfolio but overlapping BBB-crossing platform ambition and deep CNS development capability.

TypeBroad incumbent
Description

Established antisense oligonucleotide company with multiple CNS programs (e.g., ASOs for SMA, Huntington's); adjacent to Key2Brain because OliX/Key2Brain siRNA work overlaps with the oligonucleotide CNS delivery space.

TypeBroad incumbent
Description

Global leader in RNAi therapeutics with growing CNS siRNA pipeline (incl. partnerships to enable brain delivery); comparable to Key2Brain's OliX siRNA BBB shuttle work as a large incumbent pushing into CNS RNAi.

TypeEmerging player
Description

Clinical-stage oligonucleotide therapeutics company developing CNS-targeted ASOs and siRNAs; relevant emerging player with overlap to Key2Brain's oligonucleotide delivery focus.

TypeEmerging player
Description

Clinical-stage gene therapy company developing AAV-based CNS delivery platforms for neurological diseases; comparable as a non-BBB-shuttle but emerging platform approach to delivering therapeutics to the brain.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Key2Brain

CNS Drug Delivery Technologykey2brain.com

Key2Brain AB is a Swedish preclinical biotech developing a proprietary blood-brain barrier-crossing VHH antibody platform that delivers CNS therapeutics to pharmaceutical partners via worldwide licensing and collaboration agreements.

What Key2Brain does

Key2Brain AB is a Swedish privately held biotechnology company founded in 2020 and headquartered at the Karolinska Institute Campus (Innomedicum, A Working Lab) in Solna, Stockholm. The company has developed a proprietary blood-brain barrier (BBB)-crossing platform technology based on small (<15 kDa) engineered single-domain VHH antibodies with monovalent specificity for the Transferrin Receptor (TfR). This modular platform is designed to be integrated with diverse therapeutic modalities — peptides, proteins, enzymes, monoclonal antibodies, and oligonucleotides — to enable efficient brain uptake and broad CNS distribution without disrupting disease target specificity.

Key2Brain operates a pure B2B licensing and collaboration business model. The company does not develop or commercialize its own therapeutic products; instead, it provides partners with worldwide, royalty-bearing licenses to combine its BBB shuttle technology with partner therapeutic candidates, while partners fund all research, development, and commercialization. Revenue streams take the form of upfront payments, development and sales-based milestones, and tiered royalties on potential sales, supplemented by collaborative research and option agreements. The customer base is concentrated among large pharmaceutical and specialty biotechnology companies — most notably Chiesi Group (Chiesi Global Rare Diseases) under a worldwide license for BBB-crossing enzyme replacement therapies in alpha-mannosidosis and Krabbe disease (June 2025), and OliX Pharmaceuticals under an evaluation and option agreement for CNS-targeted siRNA delivery (February 2026).

The company employs 1-10 staff, has received non-dilutive grant funding of up to SEK 4 million from VINNOVA (Sweden's Innovation Agency) under its Innovative Start-ups and Deeptech Acceleration programs, and reports no publicly disclosed equity financing. Its internal pipeline and partnered programs remain at the preclinical to early research stage.

Key2Brain firmographics

Firmographics
Name
Key2Brain
Legal name
key2brain AB
Website
https://key2brain.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Short description
Key2Brain AB is a Swedish preclinical biotech developing a proprietary blood-brain barrier-crossing VHH antibody platform that delivers CNS therapeutics to pharmaceutical partners via worldwide licensing and collaboration agreements.
Ownership category
akta.pro rank

Key2Brain industry classification

Industry
Product category
CNS Drug Delivery Technology
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals

Keywords

  • Blood-brain barrier delivery
  • CNS drug delivery
  • VHH antibody platform
  • Brain targeting therapeutics
  • Enzyme replacement therapy

Where Key2Brain is headquartered

Location

Headquarters

HQ city
Stockholm
HQ country
Sweden
HQ region
Europe

Offices1 record

Markets served

Key2Brain business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Licensing Revenue: Worldwide, royalty-bearing license agreements where Key2Brain provides technology access and receives upfront payments, development and sales-based milestone payments, and tiered royalties on potential sales. Partner funds all research, development, and subsequent commercialization worldwide.
  2. Collaborative Research Payments: Joint research agreements with option structures where Key2Brain conducts evaluation-based research alongside partners, with potential for future exclusive licensing rights upon successful technical validation.

Distribution channels2 records

Marketing channels3 records

Key2Brain product offering

Product offering

Core offering

Key2Brain develops and licenses a proprietary blood-brain barrier-crossing (BBB-crossing) platform technology based on small (<15 kDa) engineered single domain VHH antibodies that bind the Transferrin Receptor (TfR). The platform is modularly applied across peptides, proteins, enzymes, monoclonal antibodies, and oligonucleotides to enable efficient brain uptake and broad distribution of CNS therapeutics, and is commercialized through worldwide, royalty-bearing license agreements and collaborative research partnerships with pharmaceutical and biotechnology companies.

Product overview

Key2Brain is a Swedish biotechnology company developing next-generation brain targeting therapeutics using its proprietary blood-brain barrier-crossing (BBB-crossing) platform technology. The platform consists of small (<15 kDa) engineered single domain VHH antibodies targeting the Transferrin Receptor (TfR), which can be integrated with various therapeutic modalities including peptides, proteins, enzymes, mAbs, and oligonucleotides. The company's pipeline programs include the aMann-K2B program for alpha-mannosidosis and BBB-crossing ERT programs for Krabbe disease, developed both internally and through partnerships with Chiesi Group and OliX Pharmaceuticals.

Differentiator

Problem solved

Functional benefit

Products and services

  • BBB-Crossing Platform Technology Proprietary blood-brain barrier-crossing technology based on small (<15 kDa) engineered single domain VHH antibodies with monovalent specificity for the Transferrin Receptor (TfR), enabling efficient brain uptake and broad distribution of CNS therapeutics across peptides, proteins, enzymes, mAbs, and oligonucleotides. Licensed to pharmaceutical and biotechnology partners for use in their therapeutic candidates.
  • aMann-K2B Program Blood-brain barrier-crossing recombinant enzyme replacement therapy program for alpha-mannosidosis, developed in collaboration with Chiesi Global Rare Diseases under a worldwide licensing agreement.
  • Krabbe Disease BBB-Crossing ERT

Quantifiable outcome

  • Demonstrated efficient brain uptake and target engagement in preclinical models

Companies that use Key2Brain

Customer profile

Segments3 records

Ideal customer profiles3 records

Key2Brain technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Key2Brain partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • OliX PharmaceuticalscoreStrategic or Co-development Partner · 10 February 2026Strategic evaluation and option agreement to develop CNS-targeted siRNA therapeutics using Key2Brain's TfR-targeted BBB shuttle technology. Joint research to assess CNS delivery efficiency and technical suitability. OliX may exercise option for worldwide exclusive license for conjugates incorporating OliX siRNA candidate with Key2Brain's TfR-targeting platform for undisclosed CNS target. Marks Key2Brain's first siRNA collaboration, highlighting platform versatility.
  • Chiesi Group (Chiesi Global Rare Diseases)coreStrategic or Co-development Partner · 11 June 2025Worldwide licensing agreement to advance two blood-brain barrier (BBB)-crossing recombinant enzyme replacement therapies (ERT) for lysosomal storage disorders including alpha-mannosidosis (aMann) and Krabbe disease (KD). Built on partnership initiated in 2022. Key2Brain receives upfront payment, development and sales-based milestone payments, and tiered royalties. Chiesi funds all research, development, and commercialization worldwide. Agreement includes framework to add additional enzymes to collaboration.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Key2Brain competitors and assessment

Company assessment

Emerging players

  • Arma Biosciences: Early-stage biotech developing TfR-based BBB shuttle technology for CNS drug delivery; an emerging player pursuing the same receptor-mediated delivery strategy as Key2Brain.
  • Wave Life Sciences: Clinical-stage oligonucleotide therapeutics company developing CNS-targeted ASOs and siRNAs; relevant emerging player with overlap to Key2Brain's oligonucleotide delivery focus.
  • Voyager Therapeutics: Clinical-stage gene therapy company developing AAV-based CNS delivery platforms for neurological diseases; comparable as a non-BBB-shuttle but emerging platform approach to delivering therapeutics to the brain.

Direct peers

  • Denali Therapeutics: Clinical-stage US biotech developing engineered protein transport vehicles (TVs) targeting TfR1 to deliver therapeutics across the BBB - the most direct competitor to Key2Brain's VHH/TfR shuttle approach. Both companies pursue partner-funded CNS delivery platforms.
  • JCR Pharmaceuticals: Japanese biopharma with its J-Brain Cargo BBB-penetrating antibody platform used to deliver enzyme replacement therapies across the BBB, including for lysosomal storage disorders - directly comparable to Key2Brain's Chiesi-partnered ERT programs.
  • Vect-Horus: French biotech whose BBB-shuttle vector platform delivers small molecules, peptides, proteins, and nucleic acids across the BBB via receptor-mediated transport - directly comparable modular shuttle technology to Key2Brain's VHH/TfR platform.
  • BioArctic: Swedish biotech developing CNS-targeted biologics (including brain-transport technologies for antibody delivery) with strong ties to the Karolinska ecosystem; a regional Swedish peer with overlapping BBB delivery and CNS focus.

Broad incumbents

  • Roche / Genentech: Large incumbent running the Brainshuttle (TfR-based) program with various partners, including in CNS; broader portfolio but overlapping BBB-crossing platform ambition and deep CNS development capability.
  • Ionis Pharmaceuticals: Established antisense oligonucleotide company with multiple CNS programs (e.g., ASOs for SMA, Huntington's); adjacent to Key2Brain because OliX/Key2Brain siRNA work overlaps with the oligonucleotide CNS delivery space.
  • Alnylam Pharmaceuticals: Global leader in RNAi therapeutics with growing CNS siRNA pipeline (incl. partnerships to enable brain delivery); comparable to Key2Brain's OliX siRNA BBB shuttle work as a large incumbent pushing into CNS RNAi.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Key2Brain social profiles

Digital presence

Key2Brain financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Key2Brain leadership team

Management profile

Number of profiles

Profiles9 records

Key2Brain funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Key2Brain M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Key2Brain

What does Key2Brain do?

Key2Brain develops and licenses a proprietary blood-brain barrier-crossing (BBB-crossing) platform technology based on small (<15 kDa) engineered single domain VHH antibodies that bind the Transferrin Receptor (TfR). The platform is modularly applied across peptides, proteins, enzymes, monoclonal antibodies, and oligonucleotides to enable efficient brain uptake and broad distribution of CNS therapeutics, and is commercialized through worldwide, royalty-bearing license agreements and collaborative research partnerships with pharmaceutical and biotechnology companies.

Is Key2Brain a public or private company?

Key2Brain is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Key2Brain founded?

Key2Brain was founded in 2020. It employs 11 to 50 people.

Where is Key2Brain based?

Key2Brain is headquartered in Stockholm, Sweden, in the Europe region.

How does Key2Brain make money?

Two revenue lines are on record. Licensing Revenue is the primary driver. The others are collaborative Research Payments.

Who are Key2Brain's main competitors?

Emerging players on record are Arma Biosciences, Wave Life Sciences and Voyager Therapeutics. Direct peers are Denali Therapeutics, JCR Pharmaceuticals, Vect-Horus and BioArctic. Broad incumbents are Roche / Genentech, Ionis Pharmaceuticals and Alnylam Pharmaceuticals.

Does Key2Brain have an API?

No public API is recorded for Key2Brain.

What industry is Key2Brain in?

Key2Brain's product category is CNS Drug Delivery Technology. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogChiesi Reports Strong FY2025 Financial and Sustainability Results and Announces Leadership Transition HighlightsChiesi reported FY2025 revenue of €3.625bn, up 8.2% at constant exchange rates, with EBITDA of €931m. The company invested €885m in R&D and announced Giuseppe Accogli's departure, with Jean-Marc Bellemin as interim CEO. It expects mid-single-digit revenue growth in 2026.GlobeNewswireChiesi Group Enters into Worldwide Licensing Agreement with Key2Brain AB to Advance Blood-Brain Barrier-Crossing Therapies for Lysosomal Storage DisordersChiesi Group and Key2Brain announced a worldwide license agreement to develop two blood-brain barrier-crossing enzyme replacement therapies for lysosomal storage disorders, including alpha-mannosidosis and Krabbe disease. Key2Brain will receive an upfront payment and milestone royalties, while Chiesi funds all R&D and commercialization. The agreement includes a framework to expand the license to additional enzymes.GlobeNewswireChiesi Group Enters into Worldwide Licensing Agreement with Key2Brain AB to Advance Blood-Brain Barrier-Crossing Therapies for Lysosomal Storage DisordersChiesi Group and Key2Brain announced a worldwide license agreement to develop two blood-brain barrier-crossing enzyme replacement therapies for lysosomal storage disorders, including alpha-mannosidosis and Krabbe disease. Key2Brain will receive an upfront payment and milestone royalties, while Chiesi funds all R&D and commercialization. The agreement may expand to additional enzymes.